Project Grant R21AG104025
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded Massachusetts General Hospital a $3.17 million Project Grant under the Aging Research program (CFDA 93.866) on February 15, 2026, to develop and test cell therapy approaches for Alzheimer's disease. The award funds research through February 14, 2030, addressing the restoration of neural circuit function through transplantation of inhibitory interneuron progenitors. The research focuses on correcting circuit hyperexcitation...
- Federal Grant Award Summary Massachusetts General Hospital's Research Management Division received a $1.37 million Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective March 1, 2026, through December 31, 2029. This four-year methodology grant funds research to assess the utility of 64-Copper-Fibrin-Binding-Probe-8 positron emission tomography (FBP8 PET) for detecting and quantifying pathological fibrin in the brain within a...
- Federal Grant Award Summary Massachusetts Institute of Technology received a $466,340 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded February 1, 2026, with completion scheduled for January 31, 2028. The grant supports the development and pilot testing of nucleic acid nanoparticles (NANPs) as a non-viral vector technology for delivering therapeutic nucleic acids—including short interfering RNAs (siRNAs), antisense...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded Massachusetts General Hospital (MGH) a $1.34 million Project Grant under the Aging Research program (CFDA 93.866) on April 15, 2026, for development and optimization of advanced high-resolution magnetic resonance imaging (MRI) methodologies to noninvasively track cerebrospinal fluid (CSF) flow dynamics and amyloid-beta (AB) diffusion through perivascular spaces (PVS). The primary deliverables include novel MR...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded a $463,000 Project Grant to Massachusetts General Hospital's Research Management Division, effective May 1, 2026 through January 31, 2031, under the Aging Research program (CFDA 93.866). This award funds basic research designed to identify and characterize cytoplasmic chromatin fragments (CCF) that accumulate during cellular senescence and aging. The research team will utilize cGAS (cyclic guanosine monophosphate–adenosine...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded a Project Grant of $157,760 to Massachusetts General Hospital's Research Management Division on August 20, 2026, under the Aging Research program (CFDA 93.866). The award supports a one-year research project investigating a novel mechanism of autophagic degradation in cellular senescence. The research focuses on understanding how autophagy—a cellular self-digestion process—functions specifically in senescent...
- Federal Grant Award Summary Massachusetts General Hospital's Research Management Division received a $269,452 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded February 18, 2026, with a completion date of November 30, 2028. The project, titled "Deciphering Proteomic Aging: From Causal Mechanisms to Frailty Prediction," delivers research services focused on identifying causal drivers of biological aging and developing...
- Federal Grant Award Summary Award Overview Massachusetts General Hospital's Research Management Division received a $679,058 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective July 1, 2026 through March 31, 2030. The award funds a mixed-methods research initiative examining the Clinical Impact of Geriatric Emergency Department Accreditation (GEDA) on older adults with dementia. The project investigates whether Emergency Department...
- Project Grant Award Summary The National Institute on Aging (NIA) awarded Massachusetts General Hospital a $660,000 Project Grant effective March 15, 2026, through February 28, 2029, under the Aging Research program (CFDA 93.866) to develop deep learning-based tools for improved Alzheimer's disease diagnosis through longitudinal structural brain magnetic resonance imaging (MRI) analysis. The project addresses a critical clinical need by creating anatomy-aware registration and morphometric...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded a $398,046 Project Grant to the Palo Alto Veterans Institute for Research (PAVIR) effective September 5, 2025, through August 31, 2027, under the Aging Research program (CFDA 93.866). The award funds a research initiative investigating the combined efficacy of anti-amyloid monoclonal antibody therapy and repetitive transcranial magnetic stimulation (rTMS) for treating mild cognitive impairment (MCI) and Alzheimer's...
The National Institute on Aging (NIA) awarded a $438,587 Project Grant to Massachusetts General Hospital (The General Hospital Corporation) on July 15, 2026, under the Aging Research program (CFDA 93.866) to develop and evaluate intranasal iron nanochelation therapy for Alzheimer's disease treatment. The award supports a 23-month research initiative (concluding June 30, 2028) conducted at MGH's Research Management Division in Charlestown, Massachusetts. The project delivers two primary research products: (1) optimized formulations of deferoxamine-coated nanochelators (DFO-NCs) based on epsilon-poly-L-lysine for intranasal administration, and (2) efficacy assessments of these nanochelators in reducing iron accumulation, neuroinflammation, and cognitive deficits using the APP/PS1 mouse model of Alzheimer's disease. The research addresses a significant gap in existing treatment approaches by developing an intranasal delivery mechanism that bypasses the blood-brain barrier, thereby improving safety and reducing systemic exposure compared to current small-molecule chelators. The deliverables from this project are expected to establish proof-of-concept for a novel, non-invasive nanochelation therapy targeting iron dysregulation as an emerging pathological driver of Alzheimer's disease. This investigator-initiated research aligns with NIA's strategic focus on understanding disease mechanisms and advancing prevention and treatment approaches for Alzheimer's disease and related dementias, contributing to the broader NIH aging research portfolio that supports biomedical investigation across academic medical centers and research institutions.Summary of Federal Project Grant Award
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $438.6k | 7/15/26 |